Previous data showed that HSP90 inhibitors can induce Bcr-Abl transportation into the nucleus and promote the apoptosis of CML cells, and the inhibitor of protein nuclear export LMB can prevent the transport of Bcr-Abl out of the nucleus. Here, HSP90AB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.